Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial

Lancet

Volumn 353, Issue 9150, 1999, Pages 345-350

  Vermorken, Jan B ^c   Claessen, Anke M E ^b   Van Tinteren, Harm ^e   Gall, Helen E ^a   Ezinga, Renate ^e   Meijer, Sybren ^a   Scheper, Rik J ^b   Meijer, Chris J L M ^b   Bloemena, Elizabeth ^b   Ransom, Janet H ^d   Hanna Jr , Michael G ^d   Pinedo, Herbert M ^a,b  

^a University Hospital   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d Intracel Corp   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 0033616482     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07186-4     Document Type: Article

References (20)

1. Cohen AM, Minskey BD, Schilsky RL. Colon cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott, 1997: 1144-97.
2. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-50.
3. Moertel C.G., Fleming T.R., Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 322:1990;352-356.
4. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 345:1995;939-944.
5. O'Connel M.J., Mailliard J.A., Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 15:1997;246-250.
6. Haller DG, Catalano PJ, MacDonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole adjuvant therapy for colon cancer: Five year final report of NT-0089. Proc Am Soc Clin Oncol 1998 (abstr).
7. Shulman K., Schilsky R.L. Adjuvant therapy of colon cancer. Semin Oncol. 2:1995;600-610.
8. Hanna M.G. Jr., Paters L.C. Specific immunotherapy of established visceral micrometastases by BCG-tumour cell vaccine alone or as an adjunct to surgery. Cancer. 42:1978;2613-2625.
9. Hanna M.G. Jr., Brandhorst J.S., Peters L.C. Active specific immunotherapy of residual micrometastasis: an evaluation of sources, doses and ratios of BCG with tumour cells. Cancer Immunol Immunother. 7:1979;165-173.
10. Peters L.C., Brandhorst J.S., Hanna M.G. Jr. Preparation of immunotherapeutic autologous vaccines from solid tumours. Cancer Res. 39:1979;1353-1360.
11. Peters L.C., Hanna M.G. Jr. Active-specific immunotherapy of established micrometasis: effect of cryopreservation procedures on tumour cell immunogenicity in guinea pigs. J Natl Cancer Inst. 64:1980;1521-1525.
12. Hoover H.C. Jr., Surdyke M., Dangel RB et al. Delayed cutaneous hypersensitivity to autologous tumour cells in colorectal cancer patients immunized with a autologous tumour cell: bacillus Calmette Guérin Vaccine. Cancer Res. 44:1984;1671-1676.
13. Hoover H.C. Jr., Surdyke M., Dangel Ret al. Prospectively randomized trail of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 55:1985;1236-1243.
14. Hoover H.C. Jr., Brandhorst J.S., Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6·5-year median follow-up of a phase II prospectively randomized trial. J Clin Oncol. 11:1993;390-399.
15. Berd D., Maguire H.C. Jr., McCue P., Mastrangelo M.J. Treatment of metastatic melanoma with an autologous tumour-cell vaccine: clinical immunologic results in 64 patients. Clin Oncol. 8:1990;1858-1867.
16. Sahasrabudhe D.M., DeKernion J.B., Pontes JE, et al. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod. 5:1986;581-588.
17. Harris J., Ryan L., Adams G, et al. Survival and relapse in adjuvant autologous tumour vaccine therapy for Dukes B and C colon cancer-EST 5283. Proc Am Soc Clin Oncol. 13:1994;294.
18. Ransom J.H., Pelle B.A., Brandhorst JS, et al. HLA-DR and ICAM-1 expression on human colon carcinoma vaccines predicts clinical response to active specific immunotherapy. Vaccine Res. 2:1993;65-78.
19. Wolmark N., Rockette H., Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Protocol C-03. J Clin Oncol. 11:1993;1879-1887.
20. Audisio R.A., Setti-Carraro P., Segala M, et al. Follow-up in colorectal cancer patients: a cost-benefit analysis. Ann Surg Oncol. 3:1996;349-357.